ProCE Banner Activity

DETERMINATION: Phase III Trial of VRd ± ASCT With Ongoing Lenalidomide Maintenance in Patients With NDMM

Slideset Download
Conference Coverage
In the phase III DETERMINATION trial, addition of ASCT to VRd induction with ongoing lenalidomide maintenance resulted in prolonged median PFS—but not OS—in newly diagnosed multiple myeloma.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab